AN2 Therapeutics

IRS: 820606654
ANTX

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Founded
2017 (6 years)
Investor RelationsSEC
Revenue
0 (2023)

Want to see more? Sign up!